These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32083235)

  • 1. Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
    Gouni-Berthold I
    J Endocr Soc; 2020 Feb; 4(2):bvz035. PubMed ID: 32083235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
    Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
    J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
    Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia.
    Kolovou G; Kolovou V; Katsiki N
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience.
    Williams K; Tickler G; Valdivielso P; Alonso J; Vera-Llonch M; Cubells L; Acaster S
    Orphanet J Rare Dis; 2023 Oct; 18(1):316. PubMed ID: 37817256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.
    Makhmudova U; Schulze PC; Lorkowski S; März W; Geiling JA; Weingärtner O
    J Med Case Rep; 2024 Jun; 18(1):278. PubMed ID: 38872171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
    Cefalù AB; D'Erasmo L; Iannuzzo G; Noto D; Giammanco A; Montali A; Zambon A; Forte F; Suppressa P; Giannini S; Barbagallo CM; Ganci A; Nardi E; Vernuccio F; Caldarella R; Ciaccio M; Arca M; Averna M
    Atherosclerosis; 2022 Oct; 359():13-19. PubMed ID: 36152419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of chylomicronemia.
    Navarro Hermoso A; Valdivielso P
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():75-79. PubMed ID: 34006359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
    Esan O; Wierzbicki AS
    Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Jones A; Peers K; Wierzbicki AS; Ramachandran R; Mansfield M; Dawson C; Ochoa-Ferraro A; Soran H; Jenkinson F; McDowell I; Downie P; Hamilton P; Jones RD
    Atherosclerosis; 2023 Jun; 375():67-74. PubMed ID: 37253281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.
    Hegele RA; Berberich AJ; Ban MR; Wang J; Digenio A; Alexander VJ; D'Erasmo L; Arca M; Jones A; Bruckert E; Stroes ES; Bergeron J; Civeira F; Witztum JL; Gaudet D
    J Clin Lipidol; 2018; 12(4):920-927.e4. PubMed ID: 29748148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
    Baass A; Paquette M; Bernard S; Hegele RA
    J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome.
    Cefalù AB; Giammanco A; Noto D; Spina R; Cabibi D; Barbagallo CM; Averna M
    Endocrine; 2021 Feb; 71(2):344-350. PubMed ID: 33006726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen.
    Isaac RH; Gonzalez-Devia D; Mendivil CO; Chapman E
    Front Allergy; 2023; 4():1201807. PubMed ID: 37361109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two successful pregnancies -in patients taking Volanesorsen for familial chylomicronemia syndrome.
    Wanninayake S; Ochoa-Ferraro A; Patel K; Ramachandran R; Wierzbicki AS; Dawson C
    JIMD Rep; 2024 Jul; 65(4):249-254. PubMed ID: 38974616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of familial chylomicronemia syndrome in Canadian patients.
    Gaudet D; Stevenson M; Komari N; Trentin G; Crowson C; Hadker N; Bernard S
    Lipids Health Dis; 2020 Jun; 19(1):120. PubMed ID: 32487261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of a Fat-Restricted Diet in Four Patients with Familial Chylomicronemia Syndrome: A Long-Term Follow-Up Study.
    Thajer A; Skacel G; de Gier C; Greber-Platzer S
    Children (Basel); 2021 Nov; 8(11):. PubMed ID: 34828789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
    Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
    J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
    Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
    N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.